APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Long-Acting Insulin Analogue

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Long-Acting Insulin Analogue Industry Growth and Trends Forecast to 2032

Report ID 174008800129 December 202595 pages

Choose your research edition.

Industry ResearchLong-Acting Insulin Analogue Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-Acting Insulin Analogue Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Long-Acting Insulin Analogue Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-Acting Insulin Analogue Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-Acting Insulin Analogue Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Long-Acting Insulin Analogue market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Long-Acting Insulin Analogue is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Long-Acting Insulin Analogue is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-Acting Insulin Analogue is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-Acting Insulin Analogue include Tonghua Dongbao Pharmaceutical, Sanofi, Novo Nordisk, The United Laboratories International Holdings, Eli Lilly and Company and Gan and Lee Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Long-Acting Insulin Analogue market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Long-Acting Insulin Analogue market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Long-Acting Insulin Analogue market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Long-Acting Insulin Analogue.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Long-Acting Insulin Analogue market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Long-Acting Insulin Analogue Market by Company

Tonghua Dongbao Pharmaceutical

Sanofi

Novo Nordisk

The United Laboratories International Holdings

Eli Lilly and Company

Gan and Lee Pharmaceuticals

Long-Acting Insulin Analogue Segment by Type

Insulin Degludec

Insulin Detemir

Insulin Glargine

Long-Acting Insulin Analogue Segment by Application

Gestational Diabetes

Type 2 Diabetes

Type 1 Diabetes

Other Diabetes

Long-Acting Insulin Analogue Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-Acting Insulin Analogue market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-Acting Insulin Analogue and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-Acting Insulin Analogue.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-Acting Insulin Analogue manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Long-Acting Insulin Analogue in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Insulin Degludec Table 2. Major Company of Insulin Detemir Table 3. Major Company of Insulin Glargine Table 4. Global Long-Acting Insulin Analogue Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Long-Acting Insulin Analogue Sales by Type (2021-2026) & (K Units) Table 6. Global Long-Acting Insulin Analogue Sales Market Share in Volume by Type (2021-2026) Table 7. Global Long-Acting Insulin Analogue Sales by Type (2021-2026) & (US$ Million) Table 8. Global Long-Acting Insulin Analogue Sales Market Share in Value by Type (2021-2026) Table 9. Global Long-Acting Insulin Analogue Price by Type (2021-2026) & (US$/Unit) Table 10. Global Long-Acting Insulin Analogue Sales by Type (2027-2032) & (K Units) Table 11. Global Long-Acting Insulin Analogue Sales Market Share in Volume by Type (2027-2032) Table 12. Global Long-Acting Insulin Analogue Sales by Type (2027-2032) & (US$ Million) Table 13. Global Long-Acting Insulin Analogue Sales Market Share in Value by Type (2027-2032) Table 14. Global Long-Acting Insulin Analogue Price by Type (2027-2032) & (US$/Unit) Table 15. North America Long-Acting Insulin Analogue Sales by Type (2021-2026) & (K Units) Table 16. North America Long-Acting Insulin Analogue Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Long-Acting Insulin Analogue Sales by Type (2021-2026) & (K Units) Table 18. Europe Long-Acting Insulin Analogue Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Long-Acting Insulin Analogue Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Long-Acting Insulin Analogue Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Long-Acting Insulin Analogue Sales by Type (2021-2026) & (K Units) Table 22. Latin America Long-Acting Insulin Analogue Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Long-Acting Insulin Analogue Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Long-Acting Insulin Analogue Sales by Type (2021-2026) & (US$ Million) Table 25. Long-Acting Insulin Analogue Industry Trends Table 26. Long-Acting Insulin Analogue Industry Drivers Table 27. Long-Acting Insulin Analogue Industry Opportunities and Challenges Table 28. Long-Acting Insulin Analogue Industry Restraints Table 29. Global Long-Acting Insulin Analogue Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Long-Acting Insulin Analogue Revenue Market Share by Company (2021-2026) Table 31. Global Long-Acting Insulin Analogue Sales by Company (2021-2026) & (K Units) Table 32. Global Long-Acting Insulin Analogue Sales Share by Company (2021-2026) Table 33. Global Long-Acting Insulin Analogue Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Long-Acting Insulin Analogue Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Long-Acting Insulin Analogue Major Company Production Sites and Headquarters Table 36. Global Long-Acting Insulin Analogue Company, Product Type & Application Table 37. Global Long-Acting Insulin Analogue Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Long-Acting Insulin Analogue by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Long-Acting Insulin Analogue Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Long-Acting Insulin Analogue Sales by Region (2021-2026) & (K Units) Table 42. Global Long-Acting Insulin Analogue Sales Market Share in Volume by Region (2021-2026) Table 43. Global Long-Acting Insulin Analogue Sales by Region (2021-2026) & (US$ Million) Table 44. Global Long-Acting Insulin Analogue Sales Market Share in Value by Region (2021-2026) Table 45. Global Long-Acting Insulin Analogue Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Long-Acting Insulin Analogue Sales by Region (2027-2032) & (K Units) Table 47. Global Long-Acting Insulin Analogue Sales Market Share in Volume by Region (2027-2032) Table 48. Global Long-Acting Insulin Analogue Sales by Region (2027-2032) & (US$ Million) Table 49. Global Long-Acting Insulin Analogue Sales Market Share in Value by Region (2027-2032) Table 50. Global Long-Acting Insulin Analogue Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Long-Acting Insulin Analogue Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Long-Acting Insulin Analogue Sales by Application (2021-2026) & (K Units) Table 53. Global Long-Acting Insulin Analogue Sales Market Share in Volume by Application (2021-2026) Table 54. Global Long-Acting Insulin Analogue Sales by Application (2021-2026) & (US$ Million) Table 55. Global Long-Acting Insulin Analogue Sales Market Share in Value by Application (2021-2026) Table 56. Global Long-Acting Insulin Analogue Price by Application (2021-2026) & (US$/Unit) Table 57. Global Long-Acting Insulin Analogue Sales by Application (2027-2032) & (K Units) Table 58. Global Long-Acting Insulin Analogue Sales Market Share in Volume by Application (2027-2032) Table 59. Global Long-Acting Insulin Analogue Sales by Application (2027-2032) & (US$ Million) Table 60. Global Long-Acting Insulin Analogue Sales Market Share in Value by Application (2027-2032) Table 61. Global Long-Acting Insulin Analogue Price by Application (2027-2032) & (US$/Unit) Table 62. North America Long-Acting Insulin Analogue Sales by Application (2021-2026) & (K Units) Table 63. North America Long-Acting Insulin Analogue Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Long-Acting Insulin Analogue Sales by Application (2021-2026) & (K Units) Table 65. Europe Long-Acting Insulin Analogue Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Long-Acting Insulin Analogue Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Long-Acting Insulin Analogue Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Long-Acting Insulin Analogue Sales by Application (2021-2026) & (K Units) Table 69. Latin America Long-Acting Insulin Analogue Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Long-Acting Insulin Analogue Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Long-Acting Insulin Analogue Sales by Application (2021-2026) & (US$ Million) Table 72. Tonghua Dongbao Pharmaceutical Company Information Table 73. Tonghua Dongbao Pharmaceutical Business Overview Table 74. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product Portfolio Table 76. Tonghua Dongbao Pharmaceutical Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Sanofi Long-Acting Insulin Analogue Product Portfolio Table 81. Sanofi Recent Development Table 82. Novo Nordisk Company Information Table 83. Novo Nordisk Business Overview Table 84. Novo Nordisk Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Novo Nordisk Long-Acting Insulin Analogue Product Portfolio Table 86. Novo Nordisk Recent Development Table 87. The United Laboratories International Holdings Company Information Table 88. The United Laboratories International Holdings Business Overview Table 89. The United Laboratories International Holdings Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. The United Laboratories International Holdings Long-Acting Insulin Analogue Product Portfolio Table 91. The United Laboratories International Holdings Recent Development Table 92. Eli Lilly and Company Company Information Table 93. Eli Lilly and Company Business Overview Table 94. Eli Lilly and Company Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Eli Lilly and Company Long-Acting Insulin Analogue Product Portfolio Table 96. Eli Lilly and Company Recent Development Table 97. Gan and Lee Pharmaceuticals Company Information Table 98. Gan and Lee Pharmaceuticals Business Overview Table 99. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product Portfolio Table 101. Gan and Lee Pharmaceuticals Recent Development Table 102. North America Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 103. North America Long-Acting Insulin Analogue Sales by Country (2021-2026) & (K Units) Table 104. North America Long-Acting Insulin Analogue Sales Market Share by Country (2021-2026) Table 105. North America Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032) & (K Units) Table 106. North America Long-Acting Insulin Analogue Sales Market Share Forecast by Country (2027-2032) Table 107. North America Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 108. North America Long-Acting Insulin Analogue Market Size by Country (2021-2026) & (US$ Million) Table 109. North America Long-Acting Insulin Analogue Market Share by Country (2021-2026) Table 110. North America Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032) & (US$ Million) Table 111. North America Long-Acting Insulin Analogue Market Share Forecast by Country (2027-2032) Table 112. Europe Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 113. Europe Long-Acting Insulin Analogue Sales by Country (2021-2026) & (K Units) Table 114. Europe Long-Acting Insulin Analogue Sales Market Share by Country (2021-2026) Table 115. Europe Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032) & (K Units) Table 116. Europe Long-Acting Insulin Analogue Sales Market Share Forecast by Country (2027-2032) Table 117. Europe Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 118. Europe Long-Acting Insulin Analogue Market Size by Country (2021-2026) & (US$ Million) Table 119. Europe Long-Acting Insulin Analogue Market Share by Country (2021-2026) Table 120. Europe Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032) & (US$ Million) Table 121. Europe Long-Acting Insulin Analogue Market Share Forecast by Country (2027-2032) Table 122. Asia-Pacific Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 123. Asia-Pacific Long-Acting Insulin Analogue Sales by Country (2021-2026) & (K Units) Table 124. Asia-Pacific Long-Acting Insulin Analogue Sales Market Share by Country (2021-2026) Table 125. Asia-Pacific Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032) & (K Units) Table 126. Asia-Pacific Long-Acting Insulin Analogue Sales Market Share Forecast by Country (2027-2032) Table 127. Asia-Pacific Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. Asia-Pacific Long-Acting Insulin Analogue Market Size by Country (2021-2026) & (US$ Million) Table 129. Asia-Pacific Long-Acting Insulin Analogue Market Share by Country (2021-2026) Table 130. Asia-Pacific Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. Asia-Pacific Long-Acting Insulin Analogue Market Share Forecast by Country (2027-2032) Table 132. Latin America Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 133. Latin America Long-Acting Insulin Analogue Sales by Country (2021-2026) & (K Units) Table 134. Latin America Long-Acting Insulin Analogue Sales Market Share by Country (2021-2026) Table 135. Latin America Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032) & (K Units) Table 136. Latin America Long-Acting Insulin Analogue Sales Market Share Forecast by Country (2027-2032) Table 137. Latin America Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Latin America Long-Acting Insulin Analogue Market Size by Country (2021-2026) & (US$ Million) Table 139. Latin America Long-Acting Insulin Analogue Market Share by Country (2021-2026) Table 140. Latin America Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Latin America Long-Acting Insulin Analogue Market Share Forecast by Country (2027-2032) Table 142. Middle East and Africa Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 143. Middle East and Africa Long-Acting Insulin Analogue Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa Long-Acting Insulin Analogue Sales Market Share by Country (2021-2026) Table 145. Middle East and Africa Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032) & (K Units) Table 146. Middle East and Africa Long-Acting Insulin Analogue Sales Market Share Forecast by Country (2027-2032) Table 147. Middle East and Africa Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Middle East and Africa Long-Acting Insulin Analogue Market Size by Country (2021-2026) & (US$ Million) Table 149. Middle East and Africa Long-Acting Insulin Analogue Market Share by Country (2021-2026) Table 150. Middle East and Africa Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Middle East and Africa Long-Acting Insulin Analogue Market Share Forecast by Country (2027-2032) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Long-Acting Insulin Analogue Distributors List Table 155. Long-Acting Insulin Analogue Customers List Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Long-Acting Insulin Analogue Image Figure 2. Global Long-Acting Insulin Analogue Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-Acting Insulin Analogue Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-Acting Insulin Analogue Sales (2021-2032) & (K Units) Figure 5. Insulin Degludec Image Figure 6. Global Insulin Degludec Sales YoY Growth (2021-2032) & (K Units) Figure 7. Insulin Detemir Image Figure 8. Global Insulin Detemir Sales YoY Growth (2021-2032) & (K Units) Figure 9. Insulin Glargine Image Figure 10. Global Insulin Glargine Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Long-Acting Insulin Analogue Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Long-Acting Insulin Analogue Market Share by Type 2025 VS 2032 Figure 13. North America Long-Acting Insulin Analogue Sales Market Share in Volume by Type in 2025 Figure 14. North America Long-Acting Insulin Analogue Sales Market Share in Value by Type in 2025 Figure 15. Europe Long-Acting Insulin Analogue Sales Market Share in Volume by Type in 2025 Figure 16. Europe Long-Acting Insulin Analogue Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Long-Acting Insulin Analogue Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Long-Acting Insulin Analogue Sales Market Share in Value by Type in 2025 Figure 19. Latin America Long-Acting Insulin Analogue Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Long-Acting Insulin Analogue Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Long-Acting Insulin Analogue Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Long-Acting Insulin Analogue Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Long-Acting Insulin Analogue Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Gestational Diabetes Image Figure 26. Global Gestational Diabetes Sales YoY Growth (2021-2032) & (K Units) Figure 27. Type 2 Diabetes Image Figure 28. Global Type 2 Diabetes Sales YoY Growth (2021-2032) & (K Units) Figure 29. Type 1 Diabetes Image Figure 30. Global Type 1 Diabetes Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Diabetes Image Figure 32. Global Other Diabetes Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Long-Acting Insulin Analogue Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Long-Acting Insulin Analogue Market Share by Application 2025 VS 2032 Figure 35. North America Long-Acting Insulin Analogue Sales Market Share in Volume by Application in 2025 Figure 36. North America Long-Acting Insulin Analogue Sales Market Share in Value by Application in 2025 Figure 37. Europe Long-Acting Insulin Analogue Sales Market Share in Volume by Application in 2025 Figure 38. Europe Long-Acting Insulin Analogue Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Long-Acting Insulin Analogue Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Long-Acting Insulin Analogue Sales Market Share in Value by Application in 2025 Figure 41. Latin America Long-Acting Insulin Analogue Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Long-Acting Insulin Analogue Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Long-Acting Insulin Analogue Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Long-Acting Insulin Analogue Sales Market Share in Value by Application in 2025 Figure 45. North America Long-Acting Insulin Analogue Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Long-Acting Insulin Analogue Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Long-Acting Insulin Analogue Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Long-Acting Insulin Analogue Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Long-Acting Insulin Analogue Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Long-Acting Insulin Analogue Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Long-Acting Insulin Analogue Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Long-Acting Insulin Analogue Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Long-Acting Insulin Analogue Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Long-Acting Insulin Analogue Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Long-Acting Insulin Analogue Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Long-Acting Insulin Analogue Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Long-Acting Insulin Analogue Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Long-Acting Insulin Analogue Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Long-Acting Insulin Analogue Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Long-Acting Insulin Analogue Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Long-Acting Insulin Analogue Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Long-Acting Insulin Analogue Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Long-Acting Insulin Analogue Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Long-Acting Insulin Analogue Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Long-Acting Insulin Analogue Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Long-Acting Insulin Analogue Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin Degludec
  • Insulin Detemir
  • Insulin Glargine
Applications
  • Gestational Diabetes
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Other Diabetes
Companies covered
  • Tonghua Dongbao Pharmaceutical
  • Sanofi
  • Novo Nordisk
  • The United Laboratories International Holdings
  • Eli Lilly and Company
  • Gan and Lee Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-Acting Insulin Analogue Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Long-Acting Insulin Analogue Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Long-Acting Insulin Analogue Market by Type
  6. 1.3.1 Insulin Degludec
  7. 1.3.2 Insulin Detemir
  8. 1.3.3 Insulin Glargine
  9. 1.4 Global Long-Acting Insulin Analogue Market Size by Type
  10. 1.4.1 Global Long-Acting Insulin Analogue Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Long-Acting Insulin Analogue Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Long-Acting Insulin Analogue Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Long-Acting Insulin Analogue Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Long-Acting Insulin Analogue Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Long-Acting Insulin Analogue Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Long-Acting Insulin Analogue Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Long-Acting Insulin Analogue Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Long-Acting Insulin Analogue Industry Trends
  2. 2.2 Long-Acting Insulin Analogue Industry Drivers
  3. 2.3 Long-Acting Insulin Analogue Industry Opportunities and Challenges
  4. 2.4 Long-Acting Insulin Analogue Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Long-Acting Insulin Analogue Revenue (2021-2026)
  2. 3.2 Global Top Players by Long-Acting Insulin Analogue Sales (2021-2026)
  3. 3.3 Global Top Players by Long-Acting Insulin Analogue Price (2021-2026)
  4. 3.4 Global Long-Acting Insulin Analogue Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-Acting Insulin Analogue Major Company Production Sites & Headquarters
  6. 3.6 Global Long-Acting Insulin Analogue Company, Product Type & Application
  7. 3.7 Global Long-Acting Insulin Analogue Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-Acting Insulin Analogue Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-Acting Insulin Analogue Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-Acting Insulin Analogue Tier 1, Tier 2, and Tier 3
4 Long-Acting Insulin Analogue Regional Status and Outlook
  1. 4.1 Global Long-Acting Insulin Analogue Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Long-Acting Insulin Analogue Historic Market Size by Region
  3. 4.2.1 Global Long-Acting Insulin Analogue Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Long-Acting Insulin Analogue Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Long-Acting Insulin Analogue Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Long-Acting Insulin Analogue Forecasted Market Size by Region
  7. 4.3.1 Global Long-Acting Insulin Analogue Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Long-Acting Insulin Analogue Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Long-Acting Insulin Analogue Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Long-Acting Insulin Analogue by Application
  1. 5.1 Long-Acting Insulin Analogue Market by Application
  2. 5.1.1 Gestational Diabetes
  3. 5.1.2 Type 2 Diabetes
  4. 5.1.3 Type 1 Diabetes
  5. 5.1.4 Other Diabetes
  6. 5.2 Global Long-Acting Insulin Analogue Market Size by Application
  7. 5.2.1 Global Long-Acting Insulin Analogue Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Long-Acting Insulin Analogue Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Long-Acting Insulin Analogue Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Long-Acting Insulin Analogue Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Long-Acting Insulin Analogue Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Long-Acting Insulin Analogue Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Long-Acting Insulin Analogue Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Long-Acting Insulin Analogue Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Tonghua Dongbao Pharmaceutical
  2. 6.1.1 Tonghua Dongbao Pharmaceutical Company Information
  3. 6.1.2 Tonghua Dongbao Pharmaceutical Business Overview
  4. 6.1.3 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product Portfolio
  6. 6.1.5 Tonghua Dongbao Pharmaceutical Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Long-Acting Insulin Analogue Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Long-Acting Insulin Analogue Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Novo Nordisk
  14. 6.3.1 Novo Nordisk Company Information
  15. 6.3.2 Novo Nordisk Business Overview
  16. 6.3.3 Novo Nordisk Long-Acting Insulin Analogue Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novo Nordisk Long-Acting Insulin Analogue Product Portfolio
  18. 6.3.5 Novo Nordisk Recent Developments
  19. 6.4 The United Laboratories International Holdings
  20. 6.4.1 The United Laboratories International Holdings Company Information
  21. 6.4.2 The United Laboratories International Holdings Business Overview
  22. 6.4.3 The United Laboratories International Holdings Long-Acting Insulin Analogue Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 The United Laboratories International Holdings Long-Acting Insulin Analogue Product Portfolio
  24. 6.4.5 The United Laboratories International Holdings Recent Developments
  25. 6.5 Eli Lilly and Company
  26. 6.5.1 Eli Lilly and Company Company Information
  27. 6.5.2 Eli Lilly and Company Business Overview
  28. 6.5.3 Eli Lilly and Company Long-Acting Insulin Analogue Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Eli Lilly and Company Long-Acting Insulin Analogue Product Portfolio
  30. 6.5.5 Eli Lilly and Company Recent Developments
  31. 6.6 Gan and Lee Pharmaceuticals
  32. 6.6.1 Gan and Lee Pharmaceuticals Company Information
  33. 6.6.2 Gan and Lee Pharmaceuticals Business Overview
  34. 6.6.3 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product Portfolio
  36. 6.6.5 Gan and Lee Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Long-Acting Insulin Analogue Sales by Country
  2. 7.1.1 North America Long-Acting Insulin Analogue Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Long-Acting Insulin Analogue Sales by Country (2021-2026)
  4. 7.1.3 North America Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032)
  5. 7.2 North America Long-Acting Insulin Analogue Market Size by Country
  6. 7.2.1 North America Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Long-Acting Insulin Analogue Market Size by Country (2021-2026)
  8. 7.2.3 North America Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Long-Acting Insulin Analogue Sales by Country
  2. 8.1.1 Europe Long-Acting Insulin Analogue Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Long-Acting Insulin Analogue Sales by Country (2021-2026)
  4. 8.1.3 Europe Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Long-Acting Insulin Analogue Market Size by Country
  6. 8.2.1 Europe Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Long-Acting Insulin Analogue Market Size by Country (2021-2026)
  8. 8.2.3 Europe Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Long-Acting Insulin Analogue Sales by Country
  2. 9.1.1 Asia-Pacific Long-Acting Insulin Analogue Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Long-Acting Insulin Analogue Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Long-Acting Insulin Analogue Market Size by Country
  6. 9.2.1 Asia-Pacific Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Long-Acting Insulin Analogue Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Long-Acting Insulin Analogue Sales by Country
  2. 10.1.1 South America Long-Acting Insulin Analogue Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Long-Acting Insulin Analogue Sales by Country (2021-2026)
  4. 10.1.3 South America Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032)
  5. 10.2 South America Long-Acting Insulin Analogue Market Size by Country
  6. 10.2.1 South America Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Long-Acting Insulin Analogue Market Size by Country (2021-2026)
  8. 10.2.3 South America Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Long-Acting Insulin Analogue Sales by Country
  2. 11.1.1 Middle East and Africa Long-Acting Insulin Analogue Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Long-Acting Insulin Analogue Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Long-Acting Insulin Analogue Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Long-Acting Insulin Analogue Market Size by Country
  6. 11.2.1 Middle East and Africa Long-Acting Insulin Analogue Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Long-Acting Insulin Analogue Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Long-Acting Insulin Analogue Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Long-Acting Insulin Analogue Value Chain Analysis
  2. 12.1.1 Long-Acting Insulin Analogue Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Long-Acting Insulin Analogue Production Mode & Process
  7. 12.2 Long-Acting Insulin Analogue Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Long-Acting Insulin Analogue Distributors
  10. 12.2.3 Long-Acting Insulin Analogue Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst